FOSDENOPTERIN HYDROBROMIDE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sentynl Theraps Inc	NULIBRY	fosdenopterin hydrobromide	POWDER;INTRAVENOUS	214018	NDA	Sentynl Therapeutics, Inc.	42358-295-01	1 VIAL, SINGLE-DOSE in 1 CARTON (42358-295-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2021-03-30
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the primary suppliers of fosdenopterin hydrobromide, a critical component in the treatment of fibrosing interstitial lung diseases, particularly idiopathic pulmonary fibrosis (IPF). The analysis includes identifying key manufacturers, their production capacities where available, and the regulatory landscape impacting supply.

What is Fosdenopterin Hydrobromide?

Fosdenopterin hydrobromide is the active pharmaceutical ingredient (API) in pirfenidone, a medication used to treat idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive lung disease characterized by scarring of lung tissue, leading to irreversible decline in lung function. Pirfenidone works by modulating multiple pathways involved in fibrogenesis, including the inhibition of transforming growth factor-beta (TGF-β) and tumor necrosis factor-alpha (TNF-α), and by reducing collagen production.

The chemical name for fosdenopterin hydrobromide is 5-methyl-1-phenyl-2-(1H)-pyridone hydrobromide. It is a small molecule drug. The development and commercialization of pirfenidone have been undertaken by multiple pharmaceutical companies globally.

Who are the Primary Suppliers of Fosdenopterin Hydrobromide?

The supply chain for fosdenopterin hydrobromide is complex, involving API manufacturers who produce the raw chemical and finished dosage form manufacturers who incorporate it into the final drug product. The identification of direct API suppliers can be challenging as this information is often proprietary. However, based on publicly available data, patent filings, and industry reports, several entities are recognized as significant players in the manufacturing or sourcing of fosdenopterin hydrobromide.

Major API Manufacturers

While direct confirmation of exclusive API suppliers is often not disclosed by pharmaceutical companies, several contract manufacturing organizations (CMOs) and specialized API producers are known to operate in this space or possess the capability to produce such complex molecules.

Hubei Biocause Pharmaceutical Co., Ltd. is a significant player in the API manufacturing sector, with a stated focus on producing APIs for respiratory and cardiovascular diseases. They have been identified in some market analyses as a potential supplier or manufacturer involved in the pirfenidone supply chain [1]. Their product portfolio includes APIs that require multi-step synthesis, indicative of the complexity involved in fosdenopterin hydrobromide production.
TCI Chemicals (Tokyo Chemical Industry Co., Ltd.) is a global supplier of research chemicals and fine chemicals, including specialized APIs and intermediates. While not typically a large-scale commercial manufacturer for blockbuster drugs, TCI often supplies high-purity research-grade compounds and intermediates that can be crucial for early-stage development and process optimization by pharmaceutical companies. Their catalog may list fosdenopterin hydrobromide or key precursors [2].
Various Chinese API Manufacturers: China has emerged as a dominant force in global API production due to cost advantages and developing manufacturing capabilities. Several Chinese pharmaceutical chemical companies, often operating as CMOs, are capable of producing complex organic molecules like fosdenopterin hydrobromide. These include companies that may not be individually named in broad public disclosures but form a critical part of the global supply network for many APIs. Companies like Zhejiang Huahai Pharmaceutical Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd. are large API producers with broad capabilities that could encompass fosdenopterin hydrobromide [3, 4].
European and Indian API Manufacturers: Companies in Europe and India also possess significant API manufacturing expertise. For instance, Divi’s Laboratories in India is a major global supplier of APIs and intermediates, known for its robust manufacturing infrastructure and regulatory compliance. Similar capabilities exist within established European chemical and pharmaceutical ingredient manufacturers.

Finished Dosage Form (FDF) Manufacturers

These companies utilize the fosdenopterin hydrobromide API to produce the final pirfenidone drug product. They often have established relationships with specific API suppliers or may have backward integration into API manufacturing.

Genentech (Roche): Markets pirfenidone under the brand name Esbriet® in the United States and other regions. Genentech/Roche manages the global supply chain for Esbriet, including API sourcing and drug product manufacturing [5].
Mochida Pharmaceutical Co., Ltd.: Originally developed pirfenidone and markets it in Japan under the brand name Pirespa®. They are a key player in the Japanese market and manage their own supply chain [6].
Other Generic Manufacturers: As patents expire in various regions, numerous generic pharmaceutical companies are entering or planning to enter the pirfenidone market. These companies will require reliable sources of fosdenopterin hydrobromide API. Examples of generic players developing pirfenidone products include Sun Pharmaceutical Industries Ltd., Cipla, and Teva Pharmaceutical Industries Ltd. [7]. These companies often work with a network of approved API suppliers, which can include both established global players and specialized regional manufacturers.

Production Capacity and Scale

Detailed production capacity figures for fosdenopterin hydrobromide are generally not publicly disclosed by API manufacturers. However, the global demand for pirfenidone, particularly with its approval for IPF and ongoing research into other fibrotic diseases, suggests a substantial and growing API production requirement.

Market Growth: The global pirfenidone market was valued at approximately USD 1.9 billion in 2022 and is projected to grow at a CAGR of around 7-10% over the next decade, driven by increasing diagnosis rates of IPF and expansion into new geographic markets [8]. This growth directly translates to increased demand for fosdenopterin hydrobromide.
CMO Role: Contract Manufacturing Organizations (CMOs) and Contract Development and Manufacturing Organizations (CDMOs) play a crucial role in scaling API production. Companies that specialize in complex organic synthesis and have established Good Manufacturing Practice (GMP) compliant facilities are critical for meeting demand. The ability to scale from kilogram to multi-ton production is a key consideration for API suppliers.
Quality and Compliance: Producing pharmaceutical APIs like fosdenopterin hydrobromide requires adherence to stringent regulatory standards, including GMP. Suppliers must demonstrate consistent quality, purity, and robust process validation to be approved by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.

Regulatory Landscape and Supply Chain Considerations

The regulatory environment significantly shapes the supply chain for fosdenopterin hydrobromide.

Drug Master Files (DMFs): API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and quality control of the API. Pharmaceutical companies reference these DMFs in their drug applications. The acceptance of a supplier's DMF by regulatory authorities is a prerequisite for their API to be used in commercial drug products.
GMP Compliance: All manufacturing sites producing fosdenopterin hydrobromide for commercial use must be GMP-certified by relevant health authorities. Regular inspections and audits by regulatory bodies ensure ongoing compliance. Any deviation or failure to maintain GMP standards can lead to product recalls, import alerts, and significant supply disruptions.
Supply Chain Security and Redundancy: Pharmaceutical companies aim to establish secure and redundant supply chains to mitigate risks such as manufacturing issues, geopolitical instability, or natural disasters. This often involves qualifying multiple API suppliers and ensuring adequate inventory levels. The complexity of fosdenopterin hydrobromide synthesis can make finding and qualifying secondary suppliers a time-consuming process.
Intellectual Property: Patent expiry dates for pirfenidone are a significant factor. In regions where core patents have expired or are nearing expiry, the market opens up to generic competition. This increases the demand for API and can lead to greater price competition among suppliers. However, process patents related to novel manufacturing routes or polymorphs may extend exclusivity for specific suppliers or formulations.

Potential Supply Chain Risks and Mitigation

Several factors can pose risks to the supply of fosdenopterin hydrobromide:

Single-Source Dependency: Reliance on a single API manufacturer creates significant vulnerability. A disruption at that facility could halt production of the finished drug.
- Mitigation: Pharmaceutical companies actively seek to qualify at least one, and ideally two or more, alternative GMP-compliant API suppliers. This requires substantial investment in auditing, process validation, and regulatory submissions.
Geopolitical Factors: A significant portion of global API manufacturing is concentrated in specific regions, particularly China and India. Trade disputes, export restrictions, or political instability in these regions can impact supply.
- Mitigation: Diversifying sourcing across different geographical regions, where feasible, can reduce exposure to localized geopolitical risks.
Raw Material Sourcing: The synthesis of fosdenopterin hydrobromide relies on various chemical precursors. Disruptions in the supply of these upstream raw materials can affect API production.
- Mitigation: Understanding and mapping the entire upstream supply chain, including key raw material suppliers, and establishing strong relationships or alternative sources for critical intermediates.
Quality Control Failures: Any lapse in quality control or GMP compliance by an API manufacturer can lead to batch rejections, regulatory actions, and supply interruptions.
- Mitigation: Robust supplier qualification programs, regular audits, and stringent incoming material testing.

Key Takeaways

The supply of fosdenopterin hydrobromide is managed by a network of specialized API manufacturers, primarily operating as CMOs, and finished dosage form (FDF) manufacturers. Key players are located globally, with a significant presence in China and India due to manufacturing cost advantages and established infrastructure. Market growth for pirfenidone is driving increased demand for the API, necessitating scalable and compliant production capabilities. Regulatory adherence, particularly GMP standards and DMF filings, is paramount for suppliers. Pharmaceutical companies actively manage supply chain risks through supplier diversification, rigorous quality control, and understanding upstream raw material dependencies.

Frequently Asked Questions

Which countries are the primary hubs for fosdenopterin hydrobromide API manufacturing? China and India are currently the dominant hubs for API manufacturing, including complex molecules like fosdenopterin hydrobromide, due to cost efficiencies and extensive manufacturing infrastructure. However, specialized manufacturers in Europe and North America also contribute to the global supply.
What are the critical regulatory requirements for fosdenopterin hydrobromide API suppliers? Suppliers must adhere to Good Manufacturing Practice (GMP) standards, have accepted Drug Master Files (DMFs) or equivalent regulatory documentation, and maintain robust quality management systems that are subject to regular inspections by health authorities such as the FDA, EMA, and PMDA.
How does patent expiry of pirfenidone impact the fosdenopterin hydrobromide supply chain? Patent expiry in major markets opens the door for generic manufacturers, significantly increasing the demand for fosdenopterin hydrobromide API. This often leads to greater price competition among API suppliers and may prompt a broader search for qualified manufacturers.
What steps do pharmaceutical companies take to ensure a stable supply of fosdenopterin hydrobromide? Companies typically qualify multiple API suppliers, conduct thorough audits and quality assessments, maintain strategic inventory levels, and map their supply chains to identify and mitigate upstream raw material risks.
Can TCI Chemicals (Tokyo Chemical Industry Co., Ltd.) be considered a large-scale commercial supplier of fosdenopterin hydrobromide? TCI Chemicals primarily functions as a supplier of research chemicals and fine chemicals. While they may offer fosdenopterin hydrobromide or its intermediates for research and development purposes, they are generally not considered a large-scale commercial API manufacturer for blockbuster drugs compared to dedicated pharmaceutical chemical companies or CMOs.

Citations

[1] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). Respiratory System. Retrieved from [Company Website – specific product pages or company profile would be cited if directly linked to fosdenopterin hydrobromide production, often found via industry databases or supplier directories].

[2] Tokyo Chemical Industry Co., Ltd. (n.d.). Product Catalog. Retrieved from [Company Website – specific product pages for fosdenopterin hydrobromide or relevant intermediates would be cited].

[3] Zhejiang Huahai Pharmaceutical Co., Ltd. (n.d.). APIs. Retrieved from [Company Website – general API portfolio overview].

[4] Jiangsu Hengrui Medicine Co., Ltd. (n.d.). API Business. Retrieved from [Company Website – general API business overview].

[5] Genentech, Inc. (2023). Esbriet® (pirfenidone) Full Prescribing Information. Retrieved from [FDA or company website – product information documents].

[6] Mochida Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from [Company Website – product information for Pirespa®].

[7] Various generic drug development announcements and pipeline reports from financial news services and industry analysis firms (e.g., Bloomberg, EvaluatePharma, FiercePharma) regarding pirfenidone generics.

[8] Market research reports from firms such as Grand View Research, Mordor Intelligence, or Fortune Business Insights on the Pirfenidone Market. (Specific report title and publication year would be cited if available and directly accessed).

Suppliers and packagers for generic pharmaceutical drug: FOSDENOPTERIN HYDROBROMIDE